Data Sheet Specifications:
Description
Monoclonal antibody of 100 μg targeting CD274 for FCM, IHC.
| Target: | CD274 |
|---|---|
| Product Type: | Antibody |
| Size: | 100 μg |
| Application: | FCM, IHC |
| Research Area / Disease: | Apoptosis |
| Conjugate: | Unlabeled |
| Antibody Type: | Monoclonal |
| Clone Number: | 27A2 |
| Concentration: | 1 mg/mL |
| Formulation: | 100 μg IgG in 100 μl volume of PBS containing 50% glycerol, pH 7.2. No preservative iscontained. |
| Isotype: | IgG2b |
| Immunogen: | Recombinant human PD-L1 extracellular domain |
| Host Species: | Mouse |
| Species Reactivity: | Human |
| Source: | This antibody was purified from hybridoma(clone 27A2) supernatant using protein A agarose. Thishybridoma was established by fusion of mouse myelomacell SP2/0 with Balb/c mouse splenocyte immunized withrecombinant human PD-L1 extracellular domain. |
| Reactivity: | This antibody reacts with CD274 antigen on Flow cytometry. |
| Gene ID Human: | 29126 |
| Gene ID Mouse: | 60533 |
| Storage Temperature: | -20°C |
| Regulatory Statement: | For Research Use Only. Not for use in diagnostic procedures. |
Citations
- Droeser RA et al. Clinical impact of programmed cell death ligand 1 expression in colorectal cancer. Eur J Cancer (2013),
- Hamanishi J et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. PNAS. 104, 3360-5 (2007),
- Hino R et al. Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer 116, 1757-66 (2010),
- Gadiot J et al. Overall survival and PD-L1 expression in metastasized malignant melanoma. Cancer 117, 2192-201 (2011),
- Schuchmann M et al. The programmed death (PD)-1/PD-ligand 1 pathway regulates graft-versus-host-reactive CD8 T cells after liver transplantation. Am J Transplant. 8, 2434-44 (2008)